Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins

Cancer Biology and Therapy

Volumn 5, Issue 1, 2006, Pages 65-70

  Tryndyak, Volodymyr P ^a   Kovalchuk, Olga ^b   Pogribny, Igor P ^a,c  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

^c Division of Biochemical Toxicology   (United States)

Author keywords

Breast cancer; DNA hypomethylation; DNA methyltransferases; Histone methylation; Histone methyltransferases; Tumor progression

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; METHYL CPG BINDING PROTEIN 2; PROTEIN; SUV4 20H2 HISTONE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MUTATION; PHENOTYPE; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

EID: 32544452237     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.1.2288     Document Type: Article

References (52)

1. Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Rev Cancer 2004; 4:143-5.
2. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92.
3. Flatau E, Bogenmann E, Jones PA. Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res 1983; 43:4901-5.
4. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucl Acid Res 1983; 11:6883-94.
5. Feinberg AP. The epigenetic of cancer etiology. Semin Cancer Biol 2004; 14:427-32.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002; 3:415-28.
7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
8. Bernardino J, Roux C, Almeida A, Vogt N, Gibaud A, Gerbault-Seureau M, Magdelenat H, Bourgeois CA, Malfoy B, Dutrillaux B. DNA hypomethylation in breast cancer: An independent parameter of tumor progression? Cancer Genet Cytogenet 1997; 97:83-9.
9. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharm 2004; 68:1187-97.
10. Soares J, Pinto AE, Cunha CV, Andre A, Barao I, Sousa JM, Cravo M. Global DNA hypomethylation in breast carcinoma (correlation with prognostic factors and tumor progression). Cancer 1999; 85:112-8.
11. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, Liaw YF. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001; 61:239-45.
12. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA patterns of human tumors. Cancer Res 2004; 64:5527-34.
13. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Rev Genet 2005; 37:899-05.
14. Karpinets TV, Foy BD. Tumorigenesis: The adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis 2005; 26:1323-1334.
15. Gaudet F, Hogson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenish R. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300:489-92.
16. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenish R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 2005; 102:13580-5.
17. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997; 94:2545-50.
18. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenish R. DNA hypomethylation leads to elevated mutation rates. Nature 1998; 395:89-93.
19. Vilain C, Vogt N, Dutrillaux B, Malfoy B. DNA methylation and chromosomeinstability in breast cancer cell lines. FEBS Lett 1999; 460:231-234.
20. Ehrlich M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, Facial Anomalies Syndrome and chromosomal rearragements. J Nutr 2002; 132:2424S-9S.
21. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Haydon C, Ropero S, Petrie C, Iyer NC, Peres-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Junuwein T, Esteller M. Loss of acetylation at Lys 16 and trimethylation of histone H4 is a common hallmark of human cancer. Nature Genetics 2005; 37:391-400.
22. Hake SB, Xiao A, Allis CD. Linking epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2004; 90:761-9.
23. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes and Development 2004; 18:2315-35.
24. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-63.
25. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3:89-95.
26. Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, Stockert JC, Robertson KD, Fuks F, Esteller M. Human DNA methyltransferase 1 is required for maintenance of histone H3 modification pattern. J Biol Chem 2004; 279:37175-84.
27. Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet AG, Laird PW, Ehrlich M. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004; 64:4472-80.
28. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokines (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004; 279:31735-44.
29. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, Nelson WG. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: Changes in chromatin structure induced by treatment with 5-aza-cytidine. Cancer Biol Ther 2004; 3:540-8.
30. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP. Role of DNA hypomethylationin the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2005; In press.
31. Jiang SY, Jordan VC. Growth regulation of estrogen receptor negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992; 84:580-91.
32. Pogribny I, Yi P, James SJ. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 1999; 262:624-8.
33. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer (Effect on the urokinase-type plasminogen activator gene production and tumor invasion). J Biol Chem 2002; 277:41571-9.
34. Agoston A, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, Hicks JL, Davidson NE, Nelson WG. Increased protein stability causes DNA methyltransferase1 dysregulation in breast cancer. J Biol Chem 2005; 280:18302-10.
35. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in uterothelial carcinomas. J Urol 2005; 173:243-6.
36. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997; 13:376-8.
37. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Ann Rev Biochem 2005; 74:481-514.
38. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 420:860-921.
39. Fazzari MJ, Greally JM. Epigenomics: Beyond CpG islands. Nat Rev Genet 2004; 5:446-55.
40. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: Implications for carcinogenesis. Lancet Oncology 2004; 5:753-8.
41. Rajapakse N, Butterworth M, Kortenkamp A. Detection of DNA strand breaks and oxidized DNA bases at the single-cell level resulting from exposure to estradiol and hydroxylated metabolites. Env Mol Mutagen 2005; 45:397-404.
42. Armenante F, Merola M, Furia A, Palmieri M. Repression of the IL-6 gene is associated with hypermethylation. Biochem Biophys Res Commun 1999; 258:644-7.
43. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein γ gene CpG island promoters its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003; 63:664-73.
44. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004; 10:8068-76.
45. Sarg B, Helliger W, Talasz H, Koutzamani E, Lindner HH. Histone H4 hyperacetylation precludes histone H4 lysine 20 trimethylation. J Biol Chem 2004; 279:53458-64.
46. Detich N, Theberge J, Szyf M. Promoter-specific activation and demethylation by MBD2/demethylase. J Biol Chem 2002; 277:35791-4.
47. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Junuwein T. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes and Dev 2004; 18:1251-62.
48. Kourmouli N, Jeppesen P, Mahadevhaiah S, Burgoyne P, Wu R, Gilbert DM, Bongiorni S, Prantera G, Fanti L, Pimpinelli S, Shi W, Fundele R, Singh P. Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J Cell Sci 2004; 117:2491-501.
49. Peters AHFM, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T. Loss of Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001; 107:323-37.
50. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt C. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436:660-5.
51. Kim KC, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 2003; 63:7619-23.
52. Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, Kouzarides T. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 2004; 119:603-14.